Deborah Smith
Oncology · Riverdale, NJNPI 1225156821
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,454 of the $1,641 with a category attached, or 88.6%. It is spread thinly across 29 manufacturers, the largest accounting for just 11.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $831 and has fallen 67.0% since, to $274 in 2025.
Across 96 payments — averaging $17.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$194
- AstraZeneca$187
- Incyte Corporation$160
- Pharmacyclics LLC, An Abbvie Company$100
- GSK$92
- E.r. Squibb & Sons, L.L.C.$74
- plus $834 from 23 others
What the payments were for
- Food & beverage$1,45489%
- Education$18811%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 15 | $194 |
| AstraZeneca | 12 | $187 |
| Incyte Corporation | 6 | $160 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $100 |
| GSK | 6 | $92 |
| E.r. Squibb & Sons, L.L.C. | 5 | $74 |
| Karyopharm Therapeutics Inc. | 5 | $73 |
| Johnson & Johnson | 4 | $72 |
| Regeneron Healthcare Solutions, Inc. | 5 | $71 |
| Astellas Pharma US Inc | 4 | $71 |
| Mirati Therapeutics, Inc. | 4 | $70 |
| AbbVie | 4 | $59 |
| AMAG Pharmaceuticals, Inc. | 3 | $41 |
| Boston Scientific | 2 | $39 |
| Legend Biotech USA Inc. | 2 | $38 |
| Daiichi Sankyo Inc. | 2 | $36 |
| Beigene USA, Inc. | 2 | $33 |
| Merck | 2 | $30 |
| Myriad Genetic Laboratories, Inc. | 2 | $29 |
| Eisai Inc. | 1 | $22 |
| Blueprint Medicines Corporation | 1 | $20 |
| Beone Medicines USA, Inc. | 1 | $20 |
| Pharmacosmos Therapeutics Inc. | 1 | $20 |
| Bayer | 1 | $18 |
| Pharmaessentia USA Corporation | 1 | $17 |
| Pfizer | 1 | $16 |
| Seagen Inc. | 1 | $15 |
| Jazz Pharmaceuticals Inc. | 1 | $14 |
| Gilead | 1 | $11 |
How this compares
$1,641 in reported general payments places this provider in the 80th percentile of 23 oncology providers in New Jersey.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PomalystPomalidomide | 13 | $290,546 |
| JakafiRuxolitinib Phosphate | 15 | $256,892 |
| BrukinsaZanubrutinib | 14 | $178,545 |
| XareltoRivaroxaban | 63 | $55,269 |
| EliquisApixaban | 55 | $44,748 |
| Imatinib Mesylate | 14 | $34,106 |
| Anastrozole | 262 | $5,682 |
| Exemestane | 28 | $5,226 |
| Enoxaparin Sodium | 13 | $4,459 |
| Hydroxyurea | 90 | $2,206 |
| Letrozole | 59 | $1,769 |
| Prochlorperazine Maleate | 75 | $1,128 |
| Acyclovir | 52 | $900 |
| Tamoxifen Citrate | 30 | $663 |
| Warfarin Sodium | 59 | $651 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| E.r. Squibb & Sons, L.L.C.Pomalyst | $74 | $290,54613 claims |
| Incyte CorporationJakafi | $160 | $256,89215 claims |
| Beigene USA, Inc.Brukinsa | $33 | $178,54514 claims |
| Johnson & JohnsonXarelto | $72 | $55,26963 claims |
| PfizerEliquis | $16 | $44,74855 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 23 oncology providers in New Jersey.
Other oncology in Riverdale
- Ann McNeillNeptune$372K
- Susan WilsonMarmora$10K
- Carol BlecherElizabeth$6K
- Wendy VogelLawrenceville$3K
- Michelyne GavinCliffside Park$2K
- Amber DelecceSewell$1K
- Jacquelynn WhiteCamden$908
- Mary KellyBerkeley Heights$799
- Dina EspositoWest Orange$620
- Carol BoyerBerkeley Heights$482
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.